Lundbeck Inc. has built a reputation as a strong partner for both U.S. and European pharmaceutical companies seeking to divest or out-license their development-stage and commercial pharmaceutical products.

To date, Lundbeck has successfully completed 10 transactions, resulting in a portfolio of 19 high-need therapies, 17 of which are approved in the U.S. Now as part of the larger global Lundbeck organization, which significantly enhanced the company's CNS development pipeline, the company has a U.S. portfolio of 30 products on the market or in development.

The company is proud of its consistent track record of quickly and successfully completing transactions with minimal disruption to the seller's organization. Our significant financial resources and highly experienced team make Lundbeck the ideal "Partner of Choice."

Lundbeck Inc. has partnered with the following companies: